Gladiator Biosciences, Inc.

United States of America

Back to Profile
1-14 of 14 for Gladiator Biosciences, Inc. Sort by
Query
Aggregations
Jurisdiction
        United States 7
        Canada 4
        World 3
Date
2021 3
2020 1
Before 2020 6
IPC Class
C07K 14/745 - Blood coagulation or fibrinolysis factors 11
C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin 10
C12N 9/74 - Thrombin 10
C07K 14/485 - Epidermal growth factor [EGF], i.e. urogastrone 7
A61K 38/18 - Growth factorsGrowth regulators 6
See more
Status
Pending 4
Registered / In Force 10
Found results for  patents

1.

GLA DOMAINS AS TARGETING AGENTS

      
Application Number 17126282
Status Pending
Filing Date 2020-12-18
First Publication Date 2021-04-22
Owner GLADIATOR BIOSCIENCES, INC. (USA)
Inventor
  • Bauzon, Maxine
  • Hermiston, Terry

Abstract

The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis. These proteins can be linked to both diagnostic and therapeutic payloads, thereby permitting identification and treatment of cells expression elevated PtdS.

IPC Classes  ?

  • A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
  • C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
  • A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
  • A61P 31/12 - Antivirals
  • C07K 14/485 - Epidermal growth factor [EGF], i.e. urogastrone
  • C07K 14/745 - Blood coagulation or fibrinolysis factors
  • C12N 9/74 - Thrombin
  • A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
  • A61K 38/18 - Growth factorsGrowth regulators
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

2.

Method of targeting exosomes

      
Application Number 16643997
Grant Number 11981723
Status In Force
Filing Date 2018-09-05
First Publication Date 2021-03-04
Grant Date 2024-05-14
Owner GLADIATOR BIOSCIENCES, INC. (USA)
Inventor
  • Hermiston, Terry
  • Bauzon, Maxine
  • Contag, Christopher H.
  • Hardy, Jonathan
  • Kanada, Masamitsu

Abstract

A method of targeting extracellular vesicles employing a molecule comprising a GLA domain and extracellular vesicles obtained or obtainable from a method are described herein.

IPC Classes  ?

  • A61K 38/36 - Blood coagulation or fibrinolysis factors
  • A61K 38/18 - Growth factorsGrowth regulators
  • A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
  • A61K 49/00 - Preparations for testing in vivo
  • C07K 14/745 - Blood coagulation or fibrinolysis factors
  • C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
  • C12N 5/0789 - Stem cellsMultipotent progenitor cells
  • C12N 5/095 - Stem cellsProgenitor cells

3.

GLA DOMAINS AS THERAPEUTIC AGENTS

      
Application Number 17032162
Status Pending
Filing Date 2020-09-25
First Publication Date 2021-01-21
Owner GLADIATOR BIOSCIENCES, INC. (USA)
Inventor
  • Bauzon, Maxine
  • Hermiston, Terry

Abstract

The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.

IPC Classes  ?

  • A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
  • C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
  • A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
  • A61P 31/12 - Antivirals
  • C07K 14/485 - Epidermal growth factor [EGF], i.e. urogastrone
  • C07K 14/745 - Blood coagulation or fibrinolysis factors
  • C12N 9/74 - Thrombin
  • A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
  • A61K 38/18 - Growth factorsGrowth regulators
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

4.

DELIVERY OF PAYLOADS TO STEM CELLS

      
Application Number 16643942
Status Pending
Filing Date 2018-09-05
First Publication Date 2020-12-31
Owner GLADIATOR BIOSCIENCES, INC. (USA)
Inventor
  • Hermiston, Terry
  • Bauzon, Maxine
  • Contag, Christopher H.
  • Hardy, Jonathan
  • Blankenberg, Francis Gerard

Abstract

The present disclosure relates to a method of targeting stems cells, in particular non-apoptotic stem cells, employing a GLA domain, capable of binding surface exposed phosphatidyl serine.

IPC Classes  ?

5.

GLA domains as therapeutic agents

      
Application Number 16170131
Grant Number 10925926
Status In Force
Filing Date 2018-10-25
First Publication Date 2019-04-11
Grant Date 2021-02-23
Owner GLADIATOR BIOSCIENCES, INC. (USA)
Inventor
  • Bauzon, Maxine
  • Hermiston, Terry

Abstract

The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.

IPC Classes  ?

  • A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
  • C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
  • A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
  • C07K 14/485 - Epidermal growth factor [EGF], i.e. urogastrone
  • C07K 14/745 - Blood coagulation or fibrinolysis factors
  • C12N 9/74 - Thrombin
  • A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
  • A61K 38/18 - Growth factorsGrowth regulators
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

6.

DELIVERY OF PAYLOADS TO STEM CELLS

      
Application Number US2018049618
Publication Number 2019/050997
Status In Force
Filing Date 2018-09-05
Publication Date 2019-03-14
Owner GLADIATOR BIOSCIENCES, INC. (USA)
Inventor
  • Hermiston, Terry
  • Bauzon, Maxine
  • Contag, Christopher, H.
  • Hardy, Jonathan
  • Blankenberg, Francis, Gerard

Abstract

The present disclosure relates to a method of targeting stems cells, in particular non-apoptotic stem cells, employing a GLA domain, capable of binding surface exposed phosphatidyl serine.

IPC Classes  ?

7.

A METHOD OF INTRACELLULAR DELIVERY

      
Application Number US2018049624
Publication Number 2019/051002
Status In Force
Filing Date 2018-09-05
Publication Date 2019-03-14
Owner GLADIATOR BIOSCIENCES, INC. (USA)
Inventor
  • Hermiston, Terry
  • Bauzon, Maxine
  • Contag, Christopher H.
  • Hardy, Jonathan
  • Blankenberg, Francis Gerard

Abstract

The present disclosure relates to a method of intracellular delivery of a molecule employing a GLA domain to facilitate entry into the cell.

IPC Classes  ?

8.

METHOD OF TARGETING EXOSOMES

      
Application Number US2018049619
Publication Number 2019/050998
Status In Force
Filing Date 2018-09-05
Publication Date 2019-03-14
Owner GLADIATOR BIOSCIENCES, INC. (USA)
Inventor
  • Hermiston, Terry
  • Bauzon, Maxine
  • Contag, Christopher H.
  • Hardy, Jonathan
  • Kanada, Masamitsu

Abstract

The present disclosure relates to a method of targeting extracellular vesicles employing a molecule comprising a GLA domain and extracellular vesicles obtained or obtainable from a method disclosed herein.

IPC Classes  ?

9.

Gla domains as targeting agents

      
Application Number 14773068
Grant Number 09694048
Status In Force
Filing Date 2014-03-13
First Publication Date 2016-04-21
Grant Date 2017-07-04
Owner GLADIATOR BIOSCIENCES, INC. (USA)
Inventor
  • Bauzon, Maxine
  • Hermiston, Terry

Abstract

The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.

IPC Classes  ?

  • A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
  • C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
  • A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
  • C07K 14/485 - Epidermal growth factor [EGF], i.e. urogastrone
  • C07K 14/745 - Blood coagulation or fibrinolysis factors
  • C12N 9/74 - Thrombin
  • A61K 38/18 - Growth factorsGrowth regulators
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

10.

Gla domains as targeting agents

      
Application Number 14772971
Grant Number 10894075
Status In Force
Filing Date 2014-03-13
First Publication Date 2016-01-14
Grant Date 2021-01-19
Owner GLADIATOR BIOSCIENCES, INC. (USA)
Inventor
  • Bauzon, Maxine
  • Hermiston, Terry

Abstract

The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis. These proteins can be linked to both diagnostic and therapeutic payloads, thereby permitting identification and treatment of cells expression elevated PtdS.

IPC Classes  ?

  • A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
  • A61P 31/12 - Antivirals
  • C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
  • A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
  • C07K 14/485 - Epidermal growth factor [EGF], i.e. urogastrone
  • C07K 14/745 - Blood coagulation or fibrinolysis factors
  • C12N 9/74 - Thrombin
  • A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
  • A61K 38/18 - Growth factorsGrowth regulators
  • A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
  • A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

11.

GLA DOMAINS AS THERAPEUTIC AGENTS

      
Document Number 02905986
Status In Force
Filing Date 2014-03-13
Grant Date 2024-09-10
Owner GLADIATOR BIOSCIENCES, INC. (USA)
Inventor
  • Bauzon, Maxine
  • Hermiston, Terry

Abstract

The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.

IPC Classes  ?

  • A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
  • A61K 47/66 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
  • A61K 49/00 - Preparations for testing in vivo
  • A61K 51/08 - Peptides, e.g. proteins
  • C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
  • C07K 14/745 - Blood coagulation or fibrinolysis factors
  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
  • C12N 9/74 - Thrombin

12.

GLA DOMAINS AS TARGETING AGENTS

      
Document Number 02905972
Status In Force
Filing Date 2014-03-13
Grant Date 2021-10-26
Owner GLADIATOR BIOSCIENCES, INC. (USA)
Inventor
  • Bauzon, Maxine
  • Hermiston, Terry

Abstract

The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis. These proteins can be linked to both diagnostic and therapeutic payloads, thereby permitting identification and treatment of cells expression elevated PtdS.

IPC Classes  ?

  • A61K 47/66 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
  • A61K 49/00 - Preparations for testing in vivo
  • A61K 51/08 - Peptides, e.g. proteins
  • A61P 31/12 - Antivirals
  • A61P 35/00 - Antineoplastic agents
  • C07K 1/13 - Labelling of peptides
  • C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
  • C07K 14/485 - Epidermal growth factor [EGF], i.e. urogastrone
  • C07K 14/745 - Blood coagulation or fibrinolysis factors
  • C07K 19/00 - Hybrid peptides
  • C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
  • G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

13.

DELIVERY OF PAYLOADS TO STEM CELLS

      
Document Number 03074291
Status Pending
Filing Date 2018-09-05
Owner GLADIATOR BIOSCIENCES, INC. (USA)
Inventor
  • Hermiston, Terry
  • Bauzon, Maxine
  • Contag, Christopher, H.
  • Hardy, Jonathan
  • Blankenberg, Francis, Gerard

Abstract

The present disclosure relates to a method of targeting stems cells, in particular non-apoptotic stem cells, employing a GLA domain, capable of binding surface exposed phosphatidyl serine.

IPC Classes  ?

14.

GLA DOMAINS AS TARGETING AGENTS

      
Document Number 03128999
Status In Force
Filing Date 2014-03-13
Grant Date 2023-09-12
Owner GLADIATOR BIOSCIENCES, INC. (USA)
Inventor
  • Bauzon, Maxine
  • Hermiston, Terry

Abstract

88910337 ABSTRACT The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis. These proteins can be linked to both diagnostic and therapeutic payloads, thereby permitting identification and treatment of cells expression elevated PtdS. Date Recue/Date Received 2021-08-26

IPC Classes  ?

  • A61K 49/00 - Preparations for testing in vivo
  • A61K 51/08 - Peptides, e.g. proteins
  • C07K 1/13 - Labelling of peptides
  • C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
  • C07K 14/485 - Epidermal growth factor [EGF], i.e. urogastrone
  • C07K 14/745 - Blood coagulation or fibrinolysis factors
  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • C07K 19/00 - Hybrid peptides
  • C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
  • C12N 9/14 - Hydrolases (3.)
  • G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor